Keywords
How to Cite
Abstract
Aim. To evaluate efficacy and safety of stereotactic ablative radiotherapy (SABR) as a radical treatment of low and intermediate risk prostate cancer (LIRPC).
Material and Methods. From April 2014 to June 2018, 111 primary patients with clinically localized LIRPC were treated with SABR as a monotherapy. SABR was delivered in 5 fractions of 7.25 Gy according to the standard technology: after 2-3 marker placement, MRI, X-ray computed tomography (CT) scanners, and using the Eclipse treatment planning system with the volumetric-modulated arc therapy (VMAT) planning. Five-year biochemical recurrence-free survival (BRFS) was assessed according to the «Phoenix definition» biochemical recurrence criteria. Toxicity was scored according to the RTOG and CTAE.
Results. The median follow-up time was 78 (60-110) months. BRFS for both the groups was 91 %: 95.5 % - for low risk and 88.2 % - for intermediate risk patients. Local control was 97.3 %. Grade II genitourinary toxicity was detected in 11 cases (10 %) and grade III in 1 case (0.9 %). Grade II rectal toxicity was observed in 6 patients (5.4 %), while no grade III toxicity was observed.
Conclusion. The results of the 5-year follow-up after SABR in LIRPC patients demonstrated the high efficacy and safety of the procedure, allowing it to be recommended for wide clinical use.
References
Lennernäs B., Majumder K., Damber J., et al. Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes. Acta Oncol. 2015; 54(6): 875-81.-DOI: https://doi.org/10.3109/0284186X.2014.974827.
Hamdy F., Donovan J., Lane J., et al. Protect Study Group. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016; 375(15): 1415-1424.-DOI: https://doi.org/10.1056/NEJMoa1606220.
Neal D.E., Metcalfe C., Donovan J.L., et al. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protect randomised controlled trial according to treatment received. Eur Urol. 2020;77(3): 320-330.-DOI: https://doi.org/10.1016/j.eururo.2019.10.030.
Гафтон Г.И., Новиков Р.В, Новиков С.Н., et al. Брахитерапия рака предстательной железы источником высокой мощности дозы в режиме монотерапии: анализ пятилетних результатов. Вопросы онкологии. 2020; 66(6): 685-694.-DOI: https://doi.org/10.37469/0507-3758-2020-66-4-404-412.
[Gafton G.I., Novikov R.V., Novikov S.N., et al. Brachytherapy of prostate cancer with a high dose rate source in monotherapy mode: an analysis of five-year results. Voprosy Onkologii = Problems in Oncology. 2020; 66(6): 685-694.-DOI: https://doi.org/10.37469/0507-3758-2020-66-4-404-412. (In Rus)].
Новиков С.Н., Канаев С.В., Новиков Р.В., и др Клинический опыт использования брахитерапии источниками высокой мощности дозы для монотерапии больных раком предстательной железы. Вопросы онкологии. 2018; 64(3): 366-373.-DOI: https://doi.org/10.37469/0507-3758-2018-64-3-366-373.
[Novikov S.N., Kanaev S.V., Novikov R.V., et al. Clinical experience of using brachytherapy with high dose rate sources for monotherapy of prostate cancer patients. Voprosy Onkologii = Problems in Oncology. 2018; 64(3): 366-373.-DOI: https://doi.org/.37469/0507-3758-2018-64-3-366-373. (In Rus)].
Behmueller M., Tselis N., Zamboglou N., et al. High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer. Oncological outcomes after a median 15-year follow-up. Front Oncol. 2021;11:770959.-DOI: https://doi.org/10.3389/fonc.2021.770959.
Viani G.A., Arruda C.V., Pellizzon A.C.A., et al. HDR brachytherapy as monotherapy for prostate cancer: A systematic review with meta-analysis. Brachytherapy. 2021; 20: 307-314.-DOI: https://doi.org/10.1016/j.brachy.2020.10.009.
Royce T.J., Wang K., Sheets N.C., et al. Tumor control probability modeling and systematic review of the literature of stereotactic body radiation therapy for prostate cancer. Int J Radiation Oncol Biol Phys. 2021; 110(1): 227-236.-DOI: https://doi.org/10.1016 /j.ijrobp.2020.08.014.
Brand D.H., Tree A.C., Ostler P., et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019; 20: 1531-43.-DOI: https://doi.org/10.1016/S1470-2045(19)30569-8.
Fransson P., Nilsson P., Gunnlaugsson A., et al. Ultra-Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol. 2021.-DOI: https://doi.org/10.1016/S1470-2045(20)30581-7.
Ильин Н.Д., Мельник Ю.С., Новиков С.Н., и др. Влияние интрафракционных смещений при проведении стереотаксической лучевой терапии рака предстательной железы на финальное распределение дозы. Вопросы онкологии. 2022; 68(2): 215-223.-DOI: https://doi.org/10.37469/0507-3758-2022-68-2-215-223.
[Ilyin N.D., Melnik Y.S., Novikov S.N. et al. Influence of intrafractional displacements during stereotactic radiotherapy of prostate cancer on the final dose distribution. Voprosy Onkologii = Problems in Oncology. 2022; 68(2): 215-223.-DOI: https://doi.org/10.37469/0507-3758-2022-68-2-215-223. (In Rus)].
Канаев С.В., Новиков С.Н., Новиков Р.В., и др. Методология стереотаксической лучевой терапии рака предстательной железы. Вопросы онкологии. 2017; 63(2): 287-293.-DOI: https://doi.org/10.37469/0507-3758-2017-63-2-287-293.
[Kanaev S.V., Novikov S.N., Novikov R.V. et al. Methodology of stereotactic radiotherapy of prostate cancer. Voprosy Onkologii = Problems in Oncology. 2017; 63(2): 287-293.-DOI: https://doi.org/10.37469/0507-3758-2017-63-2-287-293. (In Rus)].
Schaeffer E.M., Srinivas S., Adra N., et al. NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw. 2022; 20(12): 1288-1298.-DOI: https://doi.org/10.6004/jnccn.2022.0063.
US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. 2010; 80. URL: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.
Freeman D., Dickerson G., Perman M. Multi-institutional registry for prostate cancer radiosurgery: a prospective observational clinical trial. Front Oncol. 2015; 4: 369.-DOI: https://doi.org/10.3389/fonc.2014.00369.
Widmark A., Gunnlaugsson A., Beckman L., et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019; 394(10196): 385-395.-DOI: https://doi.org/10.1016/S0140-6736(19)31131-6.
Meier R.M., Bloch D.A., Cotrutz C., et al. Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints. Int J Radiat Oncol Biol Phys. 2018; 102(2): 296-303.-DOI: https://doi.org/10.1016/j.ijrobp.2018.05.040.
Andrzejewski P., Kuess P., Knausl B., et al. Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy. Radiother Oncol. 2015; 117(3): 509-514.-DOI: https://doi.org/10.1016/j.radonc.2015.07.028.
Frohlich G., Agoston P., Jorgo K., et al. Comparative dosimetrical analysis of intensity-modulated arc therapy, CyberKnife therapy and image-guided interstitial HDR and LDR brachytherapy of low risk prostate cancer. Reports of Practical Oncology and Radiotherapy. 2021; 26(2): 196-202.-DOI: https://doi.org/10.5603/RPOR.a2021.0028.
Novikov S.N., Kanaev S.V., Novikov R.V., et al. Template guided transperineal saturation biopsy of the prostate: lessons for focal and urethra-sparing high-dose-rate brachytherapy for localized prostate cancer. J Contemp Brachytherapy. 2016; 8(2): 110-115.-DOI: https://doi.org/10.5114/jcb.2016.59336.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2024